Erasca Inc
NASDAQ:ERAS
Erasca Inc
NASDAQ:ERAS
Price:
14.6
USD
-4.33%
Market Closed
Market Cap:
$4.5B
Relative Value
The Relative Value of one
ERAS
stock under the Base Case scenario is
0.36
USD.
Compared to the current market price of 14.6 USD,
Erasca Inc
is
Overvalued by 98%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
ERAS
Relative Value
Base Case
0.36
USD
Overvaluation 98%
Multiples Across Competitors
ERAS Competitors Multiples
Erasca Inc Competitors
Erasca Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Erasca Inc
NASDAQ:ERAS
|
4.1B USD | 0 | -33.3 | -30.2 | -29.5 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
362.5B USD | 5.9 | 86.6 | 14.4 | 20 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
187.5B USD | 5.1 | 24.3 | 14.1 | 14.1 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
170.3B USD | 5.8 | 20 | 12.5 | 15.5 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
115.3B USD | 9.6 | 29.2 | 21.9 | 22.9 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
77.5B USD | 5.4 | 17.2 | 12.6 | 14.4 | |
| AU |
|
CSL Ltd
ASX:CSL
|
66.8B AUD | 3.1 | 33.9 | 11.2 | 14.1 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 | |
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
41.3B USD | 11.1 | 131.9 | 73.8 | 82 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
